Caligan Partners LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001727492

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q4 2025 · 21 positions · Total reported value $1.06B · Top-10 concentration 88.9% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 25.0% · 2 new · 2 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q4 2025 13F filing, Caligan Partners LP disclosed 21 equity positions with a combined reported value of $1.06B. The filing implies a focused portfolio: its ten largest positions account for 88.9% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2025 were LQDA ($280.02M), ABVX ($195.80M), RVMD ($102.26M). By sector, the heaviest allocations are Health Care 97.9%, Other 2.1%. Versus the prior quarter, allocation shifted toward Health Care (+0.8pp) and away from Other (-0.8pp).

Versus the prior quarter, Caligan Partners LP opened 2 new positions, trimmed 2 and fully exited 3, a turnover rate of 25.0% of positions. The portfolio's overlap with the prior quarter was 52% of names.

The largest new positions opened in Q4 2025 were PCVX ($78.66M), TNGX ($33.05M), MAZE ($22.79M).

Of the 3 positions fully exited versus the prior quarter, the largest were EOLS ($25.41M), MRUS ($20.43M), SLS ($3.70M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2025)

  • PCVX VAXCYTE INC · $78.66M
  • TNGX TANGO THERAPEUTICS INC · $33.05M
  • MAZE MAZE THERAPEUTICS INC · $22.79M
  • RAPT RAPT THERAPEUTICS INC · $21.83M
  • VOR VOR BIOPHARMA INC · $9.96M
  • IVA INVENTIVA SA · $9.30M
  • SPRB SPRUCE BIOSCIENCES INC · $1.79M
  • ELDN ELEDON PHARMACEUTICALS INC · $839.53K

Fully Exited (vs previous quarter)

  • EOLS EVOLUS INC · prev qtr: $25.41M
  • MRUS MERUS N V · prev qtr: $20.43M
  • SLS SELLAS LIFE SCIENCES GROUP I · prev qtr: $3.70M
  • AURA AURA BIOSCIENCES INC · prev qtr: $1.40M · history

Insider Transactions (Form 4)

Latest Caligan Partners LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-16 Award Liquidia Corp 5,882 — SEC filing
2026-05-19 Buy Liquidia Corp 5,300 $59.98 SEC filing
2026-05-19 Sell Liquidia Corp 5,300 $59.98 SEC filing

All insider transactions →

Fund Profile

Caligan Partners LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 25 US equity positions with a combined value of $1.63B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-113810 (status: Approved), registered 2018-08-10
  • Regulatory AUM (Form ADV): $1.30B as of 2026-10-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 3 hedge funds
  • Website: caliganpartners.com

Portfolio Structure

  • 25 positions · $1.63B reported value (Q3 2026)
  • Top 10 holdings = 79.4% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 24.6%
  • Average position size: $65.36M

Sector Tilt

  • Health Care 98.2%
  • (classified holdings cover 98% of value)

Quarterly Activity

  • Q3 2026: 2 new, 12 added, 2 reduced, 3 exited
  • 9 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 97.9%
Other 2.1%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 8.12M $280.02M 26.32%
26.32%
Hold
2 1.45M $195.80M 18.40%
18.40%
Hold
3 1.28M $102.26M 9.61%
9.61%
Add
4 2.30M $83.41M 7.84%
7.84%
Reduce
5 1.70M $78.66M 7.39%
7.39%
New
6 1.55M $68.08M 6.40%
6.40%
Add
7 3.01M $54.95M 5.16%
5.16%
Add
8 3.73M $33.05M 3.11%
3.11%
New
9 944.26K $24.82M 2.33%
2.33%
Add
10 549.66K $24.64M 2.31%
2.31%
Add
11 550.19K $22.79M 2.14%
2.14%
New
12 644.40K $21.83M 2.05%
2.05%
New
13 881.53K $16.01M 1.50%
1.50%
Add
14 1.44M $13.79M 1.30%
1.30%
Hold
15 150.00K $11.85M 1.11%
1.11%
Reduce
16 925.07K $9.96M 0.94%
0.94%
New
17 2.00M $9.30M 0.87%
0.87%
New
18 923.91K $7.68M 0.72%
0.72%
Hold
19 90.00K $2.45M 0.23%
0.23%
Reduce
20 20.51K $1.79M 0.17%
0.17%
New
21 555.98K $839.53K 0.08%
0.08%
New

FAQ

What did Caligan Partners LP buy in 2025-Q4?

In its 2025-Q4 13F filing, Caligan Partners LP reported 21 equity positions worth $1.06B in aggregate; its largest disclosed positions were LQDA ($280.02M), ABVX ($195.80M), RVMD ($102.26M).

How large is Caligan Partners LP's portfolio?

Caligan Partners LP reported $1.06B of long equity holdings across 21 positions as of 2025-Q4. Top-10 holdings account for 88.9% of reported value.

What is Caligan Partners LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/caligan-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →